Maia Biotech says Phase 3 THIO-104 trial in third-line NSCLC enrolls 65 patients - MAIA News | RalliesMaia Biotech says Phase 3 THIO-104 trial in third-line NSCLC enrolls 65 patients
M
MAIA• Phase 3 trial enrollment update
- Maia Biotechnology reported progress in its pivotal Phase 3 THIO-104 trial of ateganosine as third-line therapy for advanced NSCLC.
- Enrollment reached 65 randomized patients, supporting the company’s plan to exceed 100 by year-end.
- Results were already presented as an interim assessment from the Phase 2 THIO-101 study.
- The update indicated disease control in heavily pretreated patients, outperforming typical third-line chemotherapy outcomes.
- FDA Fast Track status for NSCLC could speed review timelines, supporting a potential earlier regulatory pathway if Phase 3 data hold.
TAK
•
